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ELEVATED LEVELS OF CD191 CD21- TRANSITIONAL B CELLS IN
CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) ASSOCIATED WITH
ELEVATED PLASMA BAFF LEVELS AND BAFF RECEPTOR EXPRESSION
Rehman, N.K., Dickinson, J., Baskar, S., Rader, C., Pavletic, S.Z.,
Gress, R.E., Hakim, F.T. National Cancer Institute, NIH, Bethesda,
MD.
B Cell Activating Factor (BAFF also termed BLyS) is a critical
factor in the survival, differentiation and function of B cells, but el-
evated plasma levels of BAFF have been associated with the devel-
opment of B-cell mediated autoimmunity, both in murine models
and in human disease. In mice BAFF administration-induced auto-
immunity has been linked to increased survival of the transitional B
cell population, resulting in a failure to eliminate auto-reactive B
cell populations by negative selection during B cell maturation. Mu-
rine studies had determined that only CD211T2/T3 transitional B
cells expressed the BAFF receptor and could be rescued by elevated
BAFF levels. In contrast, in man, we have determined that the more
immature circulating CD1911CD21– T1 transitional B cell sub-
population expresses the BAFF-R to the same degree as mature B
cells in both normal donors and patient populations. We therefore
concurrently investigated both plasma BAFF levels and
CD1911CD21– T1 transitional B cell frequencies in patients en-
tered into an ongoing NCI CGVHD natural history protocol. We
determined that plasma BAFF levels were elevated in many
CGVHD patients as compared with those in normal donors
(Mann Whitney p\ 0.0001). By multi-parameter flow cytometry
we further determined that the median percentage of
CD1911CD21– T1 transitional B cells in 71 CGVHD patients
was significantly higher than that in 40 normal adult donors
(Mann Whitney p \ 0.0001). Following transplantation, the B
cell population is reconstituted primarily by maturation of new B
cells from the marrow, hence an elevated frequency of transitional
B cells would be expected when mature B cell levels are low; transi-
tional CD1911CD21- B cell frequencies remain elevated over
normal, however, even in CGVHD patients with B cell levels
greater than 100 cells/microliter (p5 .003). Comparison of patients
in the upper and lower 50th percentile of plasma BAFF levels deter-
mined that the frequency of CD21– transitional B cells was signif-
icantly higher in those patients with higher BAFF levels (p 5
.001). Elevated frequencies of CD21– B cells in CGVHD patients
may therefore reflect elevated BAFF levels. Altered transitional B
cell survival may contribute to the later generation of pathologic
auto-reactivity by the survival of auto-antigen reactive immature
B cells.355
GCSF DECREASES CD41CD251CD127LO REGULATORY T CELL PRO-
LIFERATION INDEX IN STEM CELL DONORS
Khalili, J.S., Karandish, S., Bryan, S., Molldrem, J., McMannis, J.,
Komanduri, K.V. MD Anderson Cancer Center, Houston, TX.
Increasing the number of regulatory T cells (Tregs) in donor
grafts prevents acute graft-versus-host disease (aGVHD) in murine
models of hematopoetic stem cell transplant (HSCT). It has been
reported that filgrastim (G-CSF) mobilization increases the propor-
tion of donor graft CD41CD251T cells. This finding is bolstered
by evidence from murine models, and by in vitro systems demon-
strating an impaired response to mitogenic stimulation after in
vivo G-CSF. We can now more precisely identify human Tregs
by the markers CD127lo and Foxp3. To test the hypothesis that
G-CSF increases the proportion of Tregs in human HSC donors,
we phenotyped the donor graft T cell population of 15 individuals
who had both an unmobilized DLI collected by apheresis and a sep-
arate G-CSF mobilized graft. Our phenotyping included CD4,
CD25, CD127, Foxp3, CD8, markers of memory differentiation
(CD45RA, CD27) and the cell cycle protein Ki-67. G-CSF did
not alter the total proportion of CD41CD251CD127lo Tregs in
the CD4 compartment, % Tregs baseline (mean 5 4.82, SD 5
1.08, 95% CI 5 4.30–5.42), % Tregs after G-CSF (mean 5 5.08,
SD 5 1.22, 95% CI 5 4.40–5.75). When we examined the cycling
fraction of various lymphoid subsets, we first observed that at base-line, Tregs had a much higher proliferative index (%Ki-671) than
other blood subpopulations. Furthermore, proliferation within
the Treg compartment decreased significantly following G-CSF
treatment (Table 1). We also found a G-CSF treatment-related de-
crease in proliferative index in the (non-Treg) CD41 compartment
and a trend toward increased proliferation within the B/NK com-
partment. To exclude direct effects of G-CSF on T cells we tested
for the presence of CD114 (G-CSFR) on T cells by flow cytometry,
and found none. Furthermore G-CSF treatment of PBMC (50 ng/
mL for 5 d) did not influence the proliferative index of conventional
CD41, CD81, or Tregs after in vitro T cell stimulation, suggest-
ing that the mechanism by which G-CSF reduces Treg proliferative
index in HSC donors is indirect. Since depletion of the host lym-
phoid population via conditioning presumably facilitates the expan-
sion of transferred donor graft lymphocytes, it will be important to
test if variations in the proliferative index of transferrred Tregs or
other lymphoid subsets results in an altered ‘‘proliferative momen-
tum’’ in HSCT recipients, which might influence the rate of Treg
recovery and, potentially, aGVHD rates after HSCT.Cell Population Ki-67 Proliferation Index
Non-TTreg (CD41
CD251 CD127 lo)CD41
T cellCD81
T cellcell Lymphocytes
(B cell & NK)Baseline 8.2 ± 2.5
(6.8, 9.6)2.0 ± 0.7
(1.6, 2.5)2.3 ± 1.0
(1.7, 2.8)5.1 ± 1.6
(4.2, 6.0)GCSF 6.2 ± 2.6
(4.7, 7.7)1.5 ± 0.7
(1.1, 1.9)2.9 ± 2.5
(1.5, 4.3)11.2 ± 12.1
(4.5, 17.9)t-test
(paired)\0.0001 0.01 0.36 .057Mean 6 1 SD (95% CI).356
PHASE-II STUDY OF INFLIXIMAB FOR THE PROPHYLAXIS OF ACUTE
GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT)
Hamadani, M.1, Phillips, G.2, Elder, P.1, Jansak, B.1, Blum, W.1,
Penza, S.1, Lin, T.S.1, Farag, S.S.3, Devine, S.M.1. 1Arthur G. James
Cancer Hospital, Ohio State University, Columbus, OH; 2Arthur G.
James Cancer Hospital, Ohio State University, Columbus, OH; 3 Indiana
University School of Medicine, Indianapolis, IN.
Introduction: Infliximab is a chimeric monoclonal antibody that
binds with high affinity to the soluble and transmembrane forms of
tumor necrosis factor-a, and inhibits their binding with the cellular
receptors. A number of retrospective studies have shown activity of
this drug in the treatment of steroid refractory acute (a) GVHD. We
conducted a prospective phase-II trial of infliximab for prophylaxis
of aGVHD following AHSCT. Methods: Selection criteria in-
cluded age .20 yrs, sibling (Sib) or unrelated donor (URD) avail-
ability and myeloablative (MA) AHSCT for hematologic
malignancies (except CML in 1st chronic phase and aplastic ane-
mia). Prophylaxis for aGVHD consisted of infliximab (10 mg/kg/
dose) given 1 day prior to starting MA conditioning and subse-
quently on days 0,17,114,128 and142, cyclosporine and meth-
otrexate (15 mg/m2 day 1 & 10 mg/m2 days 3,6,11). Results:
Nineteen patients (pts) were prospectively enrolled. There were
13 male and 6 female pts with a median age of 53 yrs (range 27–
64 yrs). Diagnoses included AML/MDS (n 5 11), NHL (n 5 4)
and ALL (n 5 4). Donors included matched Sib (n 5 14), matched
URD (n 5 4) and mismatched URD (n 5 1). 15 pts received MA
conditioning with busulphan/cyclophosphamide, while 4 received
TBI. All pts received peripheral blood stem cells. Prospectively en-
rolled pts getting infliximab (IG) were compared with a matched
control group (CG) (n 5 30). Pts in CG were matched for age, di-
agnosis, donor type, HLA typing, GVHD prophylaxis, condition-
ing regimen and stem cell source with IG. Median number of
CD341 cells in IG and CG was 4.95 and 5.22  106 cells/kg of
